Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 5/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25291470 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CPN1CPB2TP53TDP1 | |
| SCHEMBL25291471 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CPN1CPB2TP53TDP1 | |
| SCHEMBL2369963 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CPN1CPB2TP53TDP1 | |
| SCHEMBL25291469 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CPN1CPB2TP53TDP1 | |
| SCHEMBL3132965 | 0.92 | ALDH1A1 (0.39) | ALDH1A1CPN1CPB2TP53TDP1 | |
| SCHEMBL30478340 | 0.81 | GPR119 (0.46) | ALDH1A1DPP4MMP1MMP3MMP7 | |
| SCHEMBL25874548 | 0.81 | GPR119 (0.46) | ALDH1A1DPP4MMP1MMP3MMP7 | |
| SCHEMBL3755886 | 0.81 | CPN1 (0.32) | CPN1CPB2TP53TDP1DPP4 | |
| SCHEMBL384998 | 0.79 | GPR119 (0.44) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL866117 | 0.79 | GPR119 (0.44) | MMP1MMP3MMP7MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371401-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2021-12-02 | — | — | US | disclosed |
| US-10919879-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200207740-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3279195-B1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10421745-B2 | Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190071428-A1 | NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2019-03-07 | — | — | US | disclosed |
| US-9981949-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3279195-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | Oyster Point Pharma, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20140066460-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8633227-B2 | Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine | TARGACEPT, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130237550-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | TARGACEPT, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2544690-A2 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | Targacept Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2358670-B1 | A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor | TARGACEPT INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120157477-A1 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011112428-A2 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | TARGACEPT, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010147938-A2 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157477-A1 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNA3 | ALDH1A1 1492/4885CPN1 2055/4885CPB2 3874/4885 |
| US-20210371401-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885CPN1 1523/4885CPB2 1216/4885 |
| US-20140066460-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | ALDH1A1 2248/4885CPN1 1070/4885CPB2 1230/4885 |
| US-10919879-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885CPN1 1523/4885CPB2 1216/4885 |
| US-20200207740-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885CPN1 1523/4885CPB2 1216/4885 |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885CPN1 1523/4885CPB2 1216/4885 |
| US-20190071428-A1 | NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, SLC6A7, SLC6A5 | ALDH1A1 1805/4885CPN1 1715/4885CPB2 1060/4885 |
| US-10421745-B2 | Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, SLC6A7, NUDT5 | ALDH1A1 1893/4885CPN1 1926/4885CPB2 1428/4885 |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885CPN1 1523/4885CPB2 1216/4885 |
| US-20130237550-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | SLC10A2, MLNR, VIP | ALDH1A1 1001/4885CPN1 2254/4885CPB2 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.